Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.52B P/E - EPS this Y -39.10% Ern Qtrly Grth -
Income -296.81M Forward P/E -13.24 EPS next Y 1.50% 50D Avg Chg -6.00%
Sales 181.74M PEG -1.21 EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 7.89 EPS next 5Y 7.33% 52W High Chg -32.00%
Recommedations 2.10 Quick Ratio 3.35 Shares Outstanding 123.90M 52W Low Chg 43.00%
Insider Own 4.49% ROA -24.66% Shares Float 118.95M Beta 0.72
Inst Own 66.68% ROE -106.24% Shares Shorted/Prior 8.87M/8.84M Price 32.97
Gross Margin 100.00% Profit Margin -163.32% Avg. Volume 906,422 Target Price 55.38
Oper. Margin -3,845.26% Earnings Date Apr 30 Volume 876,899 Change -2.11%
About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals, Inc. News
04/16/24 Turnstone Biologics Appoints William Waddill to its Board of Directors
04/16/24 Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 6.6% drop adds to a year losses
04/07/24 Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
04/04/24 Insider Sell: Chief Discovery/Trans Medicine James Hamilton Sells 6,000 Shares of Arrowhead ...
04/01/24 Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
03/25/24 Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
03/11/24 The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024
03/08/24 Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares
03/08/24 Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
03/06/24 Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Expensive For A Reason? A Look At Its Intrinsic Value
03/04/24 Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
02/08/24 Arrowhead Pharmaceuticals First Quarter 2024 Earnings: Misses Expectations
02/08/24 ARWR: Pipeline Reprioritization to Reduce Cash Burn by up to $100 Million This Fiscal Year
02/07/24 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript
02/07/24 Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Call
02/06/24 Arrowhead Pharmaceuticals Inc Reports Fiscal Q1 2024 Results with Strategic Focus on ...
01/22/24 Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
01/22/24 Swelling losses haven't held back gains for Arrowhead Pharmaceuticals (NASDAQ:ARWR) shareholders since they're up 156% over 5 years
01/18/24 Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential
01/09/24 Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 16,104 Shares
ARWR Chatroom

User Image SBL71 Posted - 2 hours ago

$ARWR where it stops who the fk knows. This could go sub $20. The company with 2000 pipeline candidates and 0 going to commercial. wtf.

User Image Rabinovich Posted - 3 hours ago

$ARWR Anzalone thought he had a plan to launch endless INDs and early-stage trials and then - without much effort - quickly partner them with BP, who would sponsor his lavish pay and benefits in exchange. It went fine for a while, but then...

User Image Mattie2 Posted - 4 hours ago

$ARWR I remember a few years ago when this dropped into the $19 range and then jumped like crazy back Let’s hope for the best! It’s pretty DAGUM agitating though.

User Image CH_Expat Posted - 4 hours ago

$ARWR Nice final flush before the bell.

User Image Rabinovich Posted - 4 hours ago

$ARWR Where's the guy who was dying inside? I hope he is well.

User Image CH_Expat Posted - 5 hours ago

$ARWR We saw both. A run up and a lower Premium, f.e. at ALPN recently and the 100% double to reach the 52-week-high after a relentless selloff, for example CTIC. Something is going on here, no doubt. I made money before at ARWR from 23 to 40.

User Image skeezbag Posted - 5 hours ago

$ARWR a sustainable run is coming......get ready. Could be today or in a month but the weakness is calculated and pretty soon the fake premium will evaporate and the real premium will be built

User Image Steppinstone Posted - 6 hours ago

$ARWR Added a little bit more. Down over 25% YTD.

User Image Rabinovich Posted - 6 hours ago

$ARWR Soon the fake $45 BO offer would be a double from here, folks.

User Image skeezbag Posted - 7 hours ago

$ARWR also notice how the hedge fund call hedging action for September is now $35 and not $30...... potential little signal of flexibility on upside

User Image skeezbag Posted - 7 hours ago

$ARWR just like my friend below 👇 I added today not that it matters But for different reasons....BUYOUT

User Image Steppinstone Posted - 10 hours ago

$ARWR Added some shares today. Plozasiran should be a good drug for FCS and SHTG. I believe the last patient visit for the FCS Phase 3 Palisade trial is May 12th. After that visit then the data can be unblinded and worked up. If the data looks similar to the Phase 2 Shasta then ARWR should be okay.

User Image BiodegradableShxt Posted - 10 hours ago

$ARWR Can we get that $45 buyout please?

User Image skeezbag Posted - 10 hours ago

$ARWR here it is. The last fib level from lotto land before complete destruction

User Image skeezbag Posted - 1 day ago

$ARWR remember what yesterday's 1603 trader told you....23.68. Yup

User Image Rabinovich Posted - 1 day ago

$ARWR And Clownzalone is planning to finance a pipeline of 20 clinical assets, run CVOT and pay himself and his cronies millions in benefits, folks. WS is calling him out on his BS.

User Image skeezbag Posted - 1 day ago

$ARWR shareholders about to get really fucked or really rewarded. The problem is the probability of it all is negatively skewed

User Image skeezbag Posted - 1 day ago

$ARWR does Chris caller id know that Goldman sachs sometimes comes up as goldwoman sachs? Someone tell him

User Image johnnygogogo Posted - 1 day ago

$ARWR No investment conferences scheduled that I can find. Silence = decent chance they are selling the whole enchilada (or at least considering). And Goldman is probably their rep (why no coverage?). I don’t really care, I just hope the shorts get dusted.

User Image skeezbag Posted - 1 day ago

$ARWR only a buyout will save the mess Chris has made of this company

User Image Aigner_Andreas Posted - 1 day ago

#DeathCross $ARWR at 24.01 R15 HiLo 14% T1Y 74 buy 2.0 DIV N/A #Arrowhead #stocks #trading #finance #market

User Image Mattie2 Posted - 2 days ago

$ARWR Watching ants carry their eggs to another location is , well……AT LEAST PROGRESS

User Image Stocksrunner Posted - 2 days ago

📊 Today's Oversold Stocks: $VZIO - VIZIO Holding $WIX - Wix.com $Z - Zillow Group $ARWR - Arrowhead Pharmaceuticals $CCI - Crown Castle

User Image LeftyT Posted - 2 days ago

$ARWR Bio's under attack across the board. I guess nobody thinks they need any more new drugs to save their lives, or lose 50 lbs. I started adding more shares of arwr at 23.99 but keeping some dry powder as the whole market is looking for another good reason to tank.

User Image skeezbag Posted - 2 days ago

$ARWR the queue cards for Chris, Vinny, and Ken are being updated as we speak to blame the poor stock market in the next quarterly call

User Image skeezbag Posted - 2 days ago

$ARWR have the it's all over chants from BP in front of arrowheads new building started?

User Image Rabinovich Posted - 2 days ago

$ARWR Next fake BO offer should definitely be under $35.

User Image skeezbag Posted - 2 days ago

$ARWR 1604 trader told you 24 already. Clockwork

User Image skeezbag Posted - 2 days ago

$ARWR absolutely fucking hilarious

User Image DonCorleone77 Posted - 2 days ago

$ATHA $ARWR Athira Pharma appoints Javier San Martin as Chief Medical Officer Athira Pharma (ATHA) announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience and a proven track record leading cross-functional product teams to drive global development and commercialization strategies for multiple drugs across large and rare diseases with significant unmet medical need. San Martin joins Athira from Arrowhead Pharmaceuticals (ARWR), where he served as Chief Medical Officer and guided development teams to advance that company's RNAi-based therapeutics in the metabolic and liver disease area.

Analyst Ratings
HC Wainwright & Co. Buy Feb 8, 24
Citigroup Neutral Feb 7, 24
RBC Capital Outperform Feb 7, 24
Morgan Stanley Equal-Weight Feb 7, 24
RBC Capital Outperform Jan 16, 24
B of A Securities Buy Jan 2, 24
B of A Securities Buy Dec 4, 23
Morgan Stanley Equal-Weight Nov 30, 23
RBC Capital Outperform Nov 30, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 31 Sell 32.44 57,499 1,865,268 3,715,048 02/02/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 31 Option 14.54 57,499 836,035 3,772,547 02/02/24
Hamilton James C Chief Discovery/Tran.. Chief Discovery/Trans Medicine Jan 12 Sell 36.92 7,940 293,145 210,851 01/17/24
GIVEN DOUGLAS B Director Director Jan 11 Sell 38.16 2,911 111,084 129,711 01/16/24
Waddill William D. Director Director Jan 11 Sell 38.2 3,934 150,279 47,870 01/16/24
Ferrari Mauro Director Director Jan 11 Sell 38.22 3,147 120,278 60,778 01/16/24
Vakiener Victoria Director Director Jan 11 Sell 38.36 4,720 181,059 32,001 01/16/24
Oliver Tracie Chief Commercial Off.. Chief Commercial Officer Jan 04 Sell 33.89 74 2,508 136,501 01/08/24
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 04 Sell 34.89 16,104 561,869 440,600 01/08/24
San Martin Javier Chief Medical Office.. Chief Medical Officer Jan 04 Sell 34.93 8,303 290,024 198,497 01/08/24
Hamilton James C Other Other Jan 03 Sell 33.89 38,443 1,302,833 218,791 01/05/24
O'Brien Patrick COO and General Coun.. COO and General Counsel Jan 03 Sell 33.46 33,190 1,110,537 464,385 01/05/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 02 Sell 31 9,952 308,512 3,715,048 01/04/24
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Dec 20 Sell 28.54 12,000 342,480 3,725,000 12/22/23
San Martin Javier Chief Medical Office.. Chief Medical Officer Nov 20 Sell 28.87 19,700 568,739 131,800 11/22/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Oct 25 Sell 24.21 24,338 589,223 3,737,000 10/27/23
Vakiener Victoria Director Director Sep 28 Sell 26.33 1,550 40,812 21,734 10/02/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 18 Sell 28.14 57,755 1,625,226 3,761,338 09/20/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 18 Option 4.75 57,755 274,336 3,819,093 09/20/23
Oliver Tracie Chief Commercial Off.. Chief Commercial Officer Jul 03 Sell 35.31 8,925 315,142 61,575 07/06/23
Hamilton James C Other Other Jun 30 Sell 35.53 3,000 106,590 188,484 07/05/23
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jun 27 Sell 36.20 15,000 543,000 381,704 06/29/23
GIVEN DOUGLAS B Director Director May 05 Sell 40.90 6,500 265,850 117,635 05/08/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer May 03 Sell 39.38 104,928 4,132,065 3,761,338 05/05/23
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer May 03 Option 2.01 104,928 210,905 3,811,338 05/05/23
OLUKOTUN ADEOYE Y Director Director Mar 03 Sell 32.65 11,350 370,578 7,867 03/06/23
GIVEN DOUGLAS B Director Director Feb 27 Sell 32.62 875 28,542 13,000 03/01/23
Waddill William D. Director Director Jan 09 Sell 30 3,200 96,000 28,950 01/11/23
O'Brien Patrick COO and General Coun.. COO and General Counsel Jan 05 Sell 37.39 15,000 560,850 413,375 01/06/23
Hamilton James C Other Other Jan 05 Sell 37.4 13,803 516,232 191,484 01/06/23
Hamilton James C Other Other Jan 03 Sell 39.05 10,338 403,699 145,287 01/05/23
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Dec 29 Sell 40.00 30,625 1,225,000 336,704 12/30/22
O'Brien Patrick General Counsel General Counsel Dec 21 Option 6.15 32,000 196,800 380,875 12/22/22
San Martin Javier Chief Medical Office.. Chief Medical Officer Nov 21 Sell 30.3 19,500 590,850 91,500 11/22/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Sep 27 Option 30.99 40,624 1,258,938 3,468,314 09/29/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jul 07 Option 14.54 2,501 36,365 4,060,135 07/11/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Feb 11 Option 5.19 146,388 759,754 4,204,022 02/14/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Feb 11 Sell 51.7 146,388 7,568,260 4,057,634 02/14/22
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Jan 07 Option 5.19 11,806 61,273 4,057,634 01/07/22
O'Brien Patrick General Counsel General Counsel Jan 05 Sell 62.59 32,500 2,034,175 348,875 01/07/22
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 05 Sell 62.41 40,000 2,496,400 464,005 01/06/22
Hamilton James C Other Other Jan 04 Sell 64.84 25,625 1,661,525 155,625 01/06/22
GIVEN DOUGLAS B Director Director Dec 28 Buy 66.37 655 43,472 109,868 12/29/21
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Dec 15 Sell 68.28 60,000 4,096,800 3,219,022 12/17/21
Anzalone Christopher Richard Chief Executive Offi.. Chief Executive Officer Oct 20 Sell 65.96 65,000 4,287,400 3,279,022 10/22/21
O'Brien Patrick General Counsel General Counsel Feb 10 Option 5.22 90,000 469,800 383,375 02/10/21
O'Brien Patrick General Counsel General Counsel Feb 10 Sell 88.34 90,000 7,950,600 293,375 02/10/21
Hamilton James C Other Other Jan 15 Sell 81.4 10,000 814,000 126,250 01/15/21
Myszkowski Kenneth Allen Chief Financial Offi.. Chief Financial Officer Jan 12 Sell 81.01 13,038 1,056,208 444,005 01/12/21
O'Brien Patrick General Counsel General Counsel Jan 07 Sell 71.91 25,000 1,797,750 293,375 01/07/21